Prostaglandin E1 in infants with pulmonary atresia.
Infants with pulmonary atresia are frequently dependent upon the patency of the ductus arteriosus for adequate pulmonary blood flow. Endogenous production of a dilator prostaglandin probably maintains patency of the ductus in utero. Infusion of prostaglandin E1 (PGE1) 0,1 microgram/kg/min was used in 6 infants with pulmonary atresia to increase pulmonary blood flow and systemic oxygenation. The infusion improved the clinical condition of the infants and diminished the degree of central cyanosis. In 3 cases serial measurement of systemic arterial oxygen tension showed a sustained increase. There were no deleterious side-effects. During cardiac catheterization and preparation for operation, PGE1 provides a valuable means of maintaining pulmonary blood flow in infants with pulmonary atresia and a ductus arteriosus.
D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D008168:Lung / Q000002:abnormalities*; D008297:Male; D011458:Prostaglandins E / Q000627:therapeutic use*; D011652:Pulmonary Circulation / Q000187:drug effects
D011458:Prostaglandins E